Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer
https://doi.org/10.21518/2079-701X-2019-10-136-140
Abstract
The low efficacy of cytostatic therapy in mGC led to an active study of the role of molecular targets in the carcinogenesis of GC. Ramucirumab is the only neoangiogenesis inhibitor, which demonstrated its antitumor activity both as monotherapy and in combination with paclitaxel in patients with mGC. A clinical case demonstrated an example of a long-term (26+ months) response to paclitaxel therapy after it was combined with ramucirumab with an acceptable toxicity profile, which allowed a patient to participate in social activities and maintain quality of life.
About the Authors
T. A. Titova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Physician, Chemotherapy Department, Trapeznikov Clinical Oncology Research Institute, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
E. V. Artamonova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med.); Head of Chemotherapy Department Trapeznikov Clinical Oncology Research Institute, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
N. S. Besova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.); Head of Chemotherapy Department, Trapeznikov Clinical Oncology Research Institute, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
References
1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer Journal for Clinicians. 2018;0:1-31. doi: 10.3322/caac.21492. Available online at cacancerjournal.com.
2. Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. [The state of cancer care in Russia, 2016. Under the editorshop of A.D. Kaprina, V.V. Starinsky, G.V. Petrova. M.: Herzen Moscow Cancer Research Institute – a branch of the Federal State Budgetary Institution «National Medical Research Radiological Centre» of the Ministry of Health of Russia, 2017.] (In Russ).
3. Bang Y.-J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
4. Wilke H., Muro K., Van Cutsem E., Oh S.-C., Bodoky G., Shimada Y., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35. https ://doi.org/10.1016/S1470 -2045(14)70420-6.
5. Büyükkaramikli N.C., Blommestein H.M., Riemsma R. et al. Ramucirumab for Treating Advanced Gastric Cancer or Gastro- Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528y.
6. Makoto Natsume, Takaya Shimura, Hiroyasu Iwasaki, Yusuke Okuda et al. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-019-03817-2.
7. Fuchs C.S., Muro K., Tomasek J., et al. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Secondline Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer. 2017 Jun;17(2):132-144.
Review
For citations:
Titova TA, Artamonova EV, Besova NS. Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer. Meditsinskiy sovet = Medical Council. 2019;(10):136-140. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-136-140
Views:
606
Email this article 